Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
10.60
-0.05 (-0.47%)
Feb 27, 2026, 4:00 PM EST - Market closed
DAWN Revenue
In the year 2025, Day One Biopharmaceuticals had annual revenue of $158.18M with 20.60% growth. Day One Biopharmaceuticals had revenue of $53.72M in the quarter ending December 31, 2025, with 83.92% growth.
Revenue (ttm)
$158.18M
Revenue Growth
+20.60%
P/S Ratio
6.92
Revenue / Employee
$888,663
Employees
178
Market Cap
1.09B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 362.27M |
| MannKind | 348.97M |
| Xeris Biopharma Holdings | 266.14M |
| Geron | 183.88M |
| UroGen Pharma | 96.52M |
| AbCellera Biologics | 75.13M |
| Aktis Oncology | 5.56M |
| Inhibrx Biosciences | 1.40M |
DAWN News
- 1 day ago - Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead - Seeking Alpha
- 3 days ago - Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance - GlobeNewsWire
- 18 days ago - Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 - GlobeNewsWire
- 6 weeks ago - Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - GlobeNewsWire
- 7 weeks ago - Day One Completes Acquisition of Mersana Therapeutics - GlobeNewsWire
- 2 months ago - Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish - Seeking Alpha